Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: A review of three years prospective experience

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 110, Issue 3, 2003, Pages 281-286

  Spencer, Kevin ^a   Spencer, Christine E ^a   Power, Maureen ^a   Dawson, Carolynne ^a   Nicolaides, Kypros H ^b  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ANEUPLOIDY; ARTICLE; CHEMICAL ANALYSIS; CHROMOSOME ABERRATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ECHOGRAPHY; FEMALE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HEALTH CENTER; HIGH RISK POPULATION; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MATERNAL SERUM; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; TRISOMY 13; TRISOMY 18; TRISOMY 21;

EID: 0037333249     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-0528.2003.02246.x     Document Type: Article

References (34)

1. Spencer K. Second trimester prenatal screening for Down's syndrome using α-fetoprotein and free β-hCG: a seven year review. Br J Obstet Gynaecol. 106:1999;1287-1293.
2. Wald N.J., Kennard A., Hackshaw A., McGuire A. Antenatal screening for Down's syndrome. Health Technol Assess. 2:1998;1-112.
3. Spencer K., Mallard A.S., Coombes E.J., Macri J.N. Prenatal screening for trisomy 21 with free beta hCG as a marker. BMJ. 307:1993;1455-1458.
4. Benn P.A., Ying J., Beazoglou T., Egan J.F.X. Estimates for the sensitivity and false positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross identification and double positive results. Prenat Diagn. 21:2001;46-51.
5. Spencer K., Macri J.N., Aitken D.A., Connor J.M. Free β-hCG as a first trimester marker for fetal trisomy. Lancet. 339:1992;1480.
6. Brambati B., Lanzani A., Tului L. Ultrasound and biochemical assessment of first trimester pregnancy. Chapman M., Grudzinskas J.G., Chard T. The Embryo: Normal and Abnormal Development and Growth. 1991;181-194 Springer-Verlag, New York.
7. Nicolaides K.H., Azar G., Bryne D., Mansur C., Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester of pregnancy. BMJ. 304:1992;876-879.
8. Snijders R.J.M., Noble P., Sebire N., Souka A., Nicolaides K.H. UK multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet. 18:1999;519-521.
9. Spencer K., Souter V., Tul N., Snijders R., Nicolaides K.H. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol. 13:1999;231-237.
10. Tul N., Spencer K., Noble P., Chan C., Nicolaides K.H. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 19:2000;1035-1042.
11. Spencer K., Ong C., Skentou H., Liao A.W., Nicolaides K.H. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 20:2000a;495-499.
12. Spencer K., Tul N., Nicolaides K.H. Maternal serum free beta hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn. 20:2000;390-394.
13. Spencer K., Liao A.W.J., Skentou H., Cicero S., Nicolaides K.H. Screening for triploidy by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 20:2000;495-499.
14. Spencer K., Nicolaides K.H. A first trimester Trisomy13/Trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn. 22:2002;877-879.
15. Spencer K. Point-of-care screening for chromosomal anomalies in the first trimester of pregnancy. Clin Chem. 48:2002;403-404.
16. Spencer K. Near patient testing and Down's syndrome screening. Proc UK NEQAS. 3:1998;130.
17. Spencer K., Spencer C.E., Power M., Moakes A., Nicolaides K.H. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol. 107:2000;1271-1275.
18. Spencer K. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem. 38:2001;413-414.
19. Snijders R.J.M., Sebire N.J., Nicolaides K.H. Maternal age and gestational age specific risks for chromosomal defects. Fetal Diagn Ther. 10:1995;356-357.
20. Snijders R.J.M., Sundberg K., Holzgreve W., Henry G., Nicolaides K.H. Maternal age and gestation specific risk for trisomy 21. Ultrasound Obstet Gynecol. 13:1999;167-170.
21. Aitken D.A., McCaw G., Crossley JAet al. First trimester biochemical screening for fetal chromosomal abnormalities and neural tube defects. Prenat Diagn. 12:1993;681-689.
22. Sebire N.J., Spencer K., Noble P.L., Hughes K., Nicolaides K.H. Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation. Br J Obstet Gynaecol. 104:1997;849-851.
23. Wald N.J., Cuckle H., Brock JHet al. Report of the UK Collaborative study on alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancet. 1:1997;1323-1332.
24. Snijders R.J.M., Brizot M.L., Faria M., Nicolaides K.H. Fetal exomphalos at 11-14 weeks of gestation. J Ultrasound Med. 14:1995;569-574.
25. Johnson S.P., Sebire N.J., Snijders R.J.M., Tunkel S., Nicolaides K.H. Ultrasound screening for anencephaly at 10-14 weeks of gestation. Ultrasound Obstet Gynecol. 9:1996;14-16.
26. Nicolaides K.H., Campbell S., Gabbe S.G., Guidetti R. Ultrasound screening for spina bifida: cranial and cerebellar signs. Lancet. 2:1986;72-74.
27. Spencer K. What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester. Prenat Diagn. 21:2001;788-789.
28. Grudzinskas J.G., Ward R.H.T. Screening for Down Syndrome in the First Trimester. 1997;RCOG Press, London.
29. Brizot M.L., Snijders R.J.M., Bersinger N.A., Kohn P., Nicolaides K.H. Maternal serum pregnancy associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol. 84:1994;918-922.
30. Wald N.J., Hackshaw A.K. Combining ultrasound and biochemistry in first trimester screening for Down's syndrome. Prenat Diagn. 17:1997;821-829.
31. Orlandi F., Damiani G., Hallahan T.W., Krantz D.A., Macri J.N. First trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol. 6:1997;381-386.
32. Cuckle H.S., van Lith J.M.M. Appropriate biochemical parameters in first trimester screening for Down Syndrome. Prenat Diagn. 19:1999;505-512.
33. Krantz D.A., Hallahan T.W., Orlandi F., Buchanan P., Larsen J.W., Macri J.N. First trimester Down syndrome screening using dried blood and nuchal translucency. Obstet Gynecol. 96:2000;207-213.
34. Cuckle H. Time for a total shift to first trimester screening for Down's Syndrome. Lancet. 358:2001;1658-1659.